Next Article in Journal
Post-Operative Medium- and Long-Term Endocrine Outcomes in Patients with Non-Functioning Pituitary Adenomas—Machine Learning Analysis
Next Article in Special Issue
Maintaining Engagement in Adults with Neurofibromatosis Type 1 to Use the iCanCope Mobile Application (iCanCope-NF)
Previous Article in Journal
Development of a Machine Learning Model to Predict Recurrence of Oral Tongue Squamous Cell Carcinoma
Previous Article in Special Issue
Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 10
10.3390/cancers15102770
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Dermatologic Manifestations of Neurofibromatosis Type 1 and Emerging Treatments

Cancers 2023, 15(10), 2770; https://doi.org/10.3390/cancers15102770
by Dina Poplausky 1, Jade N. Young 1, Hansen Tai 1, Ryan Rivera-Oyola 1, Nicholas Gulati 1 and Rebecca M. Brown 2,*
Reviewer 1:
Stefan Linsler
Reviewer 2:
Shahab Uddin
Reviewer 3:
James Angelastro
Cancers 2023, 15(10), 2770; https://doi.org/10.3390/cancers15102770
Submission received: 29 March 2023 / Revised: 21 April 2023 / Accepted: 26 April 2023 / Published: 16 May 2023
(This article belongs to the Special Issue Frontiers in Neurofibromatosis)

Round 1

Reviewer 1 Report

The authors present a review of NF1 dermatologic manifestation and  emerging treatment options. The manuscripts includes cutaneous neuro- 22 fibromas, plexiform neurofibromas, diffuse neurofibromas, distinct nodular lesions, malignant pe- 23 ripheral nerve sheath tumors, glomus tumors, juvenile xanthogranulomas, skin cancer, and cutane- 24 ous T-cell lymphoma. The authors discuss and present topical, systemic and laser, light based and  surgical treatment options as well.

The manuscript is well written and the scientific aspect is well discussed. However, I would suggest some additional aspects to improve the content for the readers:

- please add a table of different studies and results

- discuss the results of previous publications regarding outcome and prognosis after treatment

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

 

 

The authors have highlighted the role of Neurofibromatosis Type 1 (NF1) in various skin-related diseases including  cutaneous neurofibromas, plexiform neurofibromas, diffuse neurofibromas, distinct nodular lesions, malignant peripheral nerve sheath tumors, glomus tumors, juvenile xanthogranulomas, skin cancer, and cutaneous T-cell lymphoma. The article covered all the mentioned aspects very elegantly with illustrations. This is an excellent article in the field and will be beneficial to the audience of this area. 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 3 Report

Dear, All,

 

 

The manuscript reviews neurofibromatosis type 1 concerning limited therapeutic options and emerging therapeutics. The review covers the full spectrum of the aspects of neurofibromatosis type 1. The manuscript has minor revisions. 

 

Minor revision.

(1) Lines 60-61 Sentence: “Genetic testing is not required for the diagnosis of NF1 but may contribute to a diagnosis.” The sentence needs clarification regarding the subject.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop